Patent Issued for Non-invasive determination of likely response to combination therapies for cardiovascular disease (USPTO 11869186).
In: Heart Disease Weekly, 2024-01-29, S. 1559-1559
serialPeriodical
Zugriff:
Elucid Bioimaging Inc. has been issued a patent for a non-invasive method of determining the likely response to combination therapies for cardiovascular disease. The patent describes a system that analyzes imaging data of arteries from patients with atherosclerosis to predict proteomic and genomic information. Healthcare providers can then use this information to simulate potential therapies and provide personalized recommendations for pharmacotherapies and procedural interventions. The patent also includes methods for obtaining proteomic and genetic information and building in silico systems biology models. This technology aims to address the need for tailored treatment plans for patients with cardiovascular disease. [Extracted from the article]
Copyright of Heart Disease Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Non-invasive determination of likely response to combination therapies for cardiovascular disease (USPTO 11869186).
|
---|---|
Zeitschrift: | Heart Disease Weekly, 2024-01-29, S. 1559-1559 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1531-6408 (print) |
Schlagwort: |
|
Sonstiges: |
|